Open AccessThe Neuroinflammasome in Alzheimer’s Disease and Cerebral Stroke
Author(s) -
Lee Jong-hoon,
Lee Chul Joong,
Park Jungwuk,
Lee So Jeong,
Choi Su-hee
Publication year - 2021
Publication title -
dementia and geriatric cognitive disorders extra
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.787
H-Index - 16
ISSN - 1664-5464
DOI - 10.1159/000516074
Subject(s) - research article
Aim/Background: This review investigated a patient with Alzheimer’s disease (AD) treated with 4,4’-diaminodiphenyl sulfone (DDS) as a neuroinflammasome competitor. Methods: We monitored AD’s progression through numeric clinical staging (NCS) with a new biomarker. NCS was determined by the presence of AD symptoms and neuropsychiatric (NP) symptoms caused by anti-AD (AAD) drugs (D) as a biomarker. We also monitored the function of DDS for stroke in a no-intake emergency state. Results: By introducing (D), AD’s progression was monitored through NCS staging. AAD side effects and neuropsychiatric symptoms were identified. DDS was stopped in patients with stroke with NCS 6 caused by AAD, and it rapidly proceeded to cerebral infarct. Conclusions: AAD can occasionally exacerbate AD and stroke. DDS can alleviate mild cognitive impairment (MCI), early AD and stroke. We clinically confirmed the role of DDS as a neuroinflammasome competitor after stroke. DDS preserved neuronal survival within 24–55 h in the Seoul Study cohort.